Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1479612 | 1.00 | NAAA (0.48) | NAAAEPHX1TSHRHTR2CNOD1 | |
| SCHEMBL7781968 | 1.00 | NAAA (0.48) | NAAAEPHX1TSHRHTR2CNOD1 | |
| SCHEMBL10546836 | 1.00 | NAAA (0.48) | NAAAEPHX1TSHRHTR2CNOD1 | |
| SCHEMBL7781970 | 1.00 | NAAA (0.48) | NAAAEPHX1TSHRHTR2CNOD1 | |
| SCHEMBL7779373 | 1.00 | NAAA (0.48) | NAAAEPHX1TSHRHTR2CNOD1 | |
| SCHEMBL10347081 | 1.00 | NAAA (0.48) | NAAAEPHX1TSHRHTR2CNOD1 | |
| SCHEMBL1479485 | 1.00 | NAAA (0.48) | NAAAEPHX1TSHRHTR2CNOD1 | |
| SCHEMBL1479487 | 1.00 | NAAA (0.48) | NAAAEPHX1TSHRHTR2CNOD1 | |
| SCHEMBL16007211 | 1.00 | NAAA (0.48) | NAAAEPHX1TSHRHTR2CNOD1 | |
| SCHEMBL7779371 | 1.00 | NAAA (0.48) | NAAAEPHX1TSHRHTR2CNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160317435-A1 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY OF CAFFEINE IN THE FORM OF SOLUTIONS OR SUSPENSIONS | SPRAYABLE HOLDINGS, INC. | 2016-11-03 | — | — | US | disclosed |
| US-9211249-B2 | Methods and compositions for transdermal delivery of caffeine in the form of solutions or suspensions | SPRAYABLE HOLDINGS, INC. | 2015-12-15 | — | — | US | disclosed |
| US-20140256749-A1 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY OF CAFFEINE IN THE FORM OF SOLUTIONS OR SUSPENSIONS | SPRAYABLE HOLDINGS, INC. | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256749-A1 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY OF CAFFEINE IN THE FORM OF SOLUTIONS OR SUSPENSIONS | TES, CCR7, CES2 | NAAA 1065/4885EPHX1 120/4885TSHR 3430/4885 |
| US-20160317435-A1 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY OF CAFFEINE IN THE FORM OF SOLUTIONS OR SUSPENSIONS | TES, CCR7, CES2 | NAAA 1065/4885EPHX1 120/4885TSHR 3430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.